NCT06158386招募中2 期
A Multicenter, Prospective, Single-arm Clinical Study on the Treatment of Refractory/Relapsed Follicular Lymphoma (R/RFL) With Chidamide Combined With Linperlisib
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Complete response rate (CR)
研究概览
简要总结
To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
详细描述
This is a Phase 2, open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The patients diagnosed with follicular lymphoma with grade 1-3a, have received at least second-line systemic treatment, and at least one of the first-line treatments includes anti-CD20 monoclonal antibody (anti-CD20 monoclonal antibody monotherapy or combined chemotherapy). If the latest histopathological diagnosis is more than 6 months, a lymph node or tissue puncture or biopsy (resection or coarse needle puncture) must be performed.
- •Age ≥18 years old, regardless of gender.
- •The estimated survival time is more than 3 months.
- •Be able to follow the requirements of the research plan.
- •The patients have at least one measurable lesion (any length of lymph node lesion > 1.5cm or any length of extranodal lesion > 1 cm) examined by computed tomography (CT)/ magnetic resonance imaging (MRI).
- •Be able to understand and voluntarily provide informed consent.
排除标准
- •CNS involvement (current or previous).
- •Clinical evidence of transformation to a more aggressive subtype of lymphoma
- •Impaired bone marrow function: neutrophils < 1.5× 10*9/L, HB < 80 g/L, PLT < 75×10*9 /L, Impaired liver function, defined as serum total bilirubin > 1.5 x ULN or serum ALT and AST > 2.5x ULN, Patients with liver infiltration by lymphoma, AST and ALT > 5x ULN, Renal glomerular filtration rate (eGFR) < 30 ml/min.
- •PT INR>1.5ULN or APTT> 1.5 ULN, Serum amylase or lipase > 1ULN.
- •Patients with active infection of the human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), if patients with HBV infection with HBsAg or hepatitis B core antibody (HBcAb) positive] but HBV DNA negative can be included, However, these patients need continuous antiviral treatment and HBV DNA PCR detection every cycle after enrollment.
- •Patients with CMV infection (IgM positive or CMV DNA was positive by PCR.)
- •Meet any of the following criteria related to visceral function: all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )<40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mgHg).
- •Have a history of stroke or intracranial hemorrhage within 6 months before drug administration for the first time.
- •Major surgery was performed within 4 weeks before enrollment.
- •Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use).
- •Received systemic anti-tumor therapy or radiotherapy within 4 weeks before enrollment.
- •The last time you participated in clinical trials of other drugs before enrollment was less than 2 weeks or the last time you used small molecular drugs (such as antibody drugs) was less than 4 weeks.
- •The patients received the transplantation of somatic hematopoietic stem cells within 3 months before enrollment.
- •Patients received allogeneic hematopoietic stem cell transplantation or had any active graft-versus-host disease within 6 months before drug administration.
- •Take a strong inducer or inhibitor of cytochrome P4503A4 (CYP3A4) within 2 weeks before the first drug administration (3 weeks for Hypericum perforatum)
- •Before the first drug administration, the toxic reaction of previous anti-tumor therapy has not recovered to ≤1 level (except alopecia).
- •Patients with uncontrolled systemic infection requiring intravenous antibiotic treatment.
- •Currently suffering from other primary tumors that need active treatment according to the guidelines.
- •Inability to take drugs orally, previous surgical history, or serious gastrointestinal diseases such as dysphagia and active gastric ulcer may affect the absorption of drugs.
- •Pregnant (serum pregnancy test results are positive) or lactating women
- •Any other diseases, abnormal metabolism, abnormal physical examination, or abnormal laboratory examination with significant clinical significance, according to the researcher's judgment, it is reasonable to suspect that the patient has a certain disease or state that is not suitable for using these two drugs, or it will affect the interpretation of the research results or put the patient in a high-risk situation.
研究组 & 干预措施
Chidamide combined with Linperlisib
Experimental
干预措施: Chidamide combined with Linperlisib (Drug)
结局指标
主要结局
Complete response rate (CR)
时间窗: Up to 24 months
CR was defined as the percentage of participants who achieved CR, using the Lugano criteria.
次要结局
- Overall response rate (ORR)(Up to 24 months)
- Progressive free survival (PFS)(Up to 24 months)
- Overall survival (OS)(Up to 24 months)
研究者
Bing, Xu
Principal Investigator
The First Affiliated Hospital of Xiamen University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell LymphomaPeripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaRefractory T-Cell LymphomaNCT06151106The First Affiliated Hospital of Xiamen University33
Unknown
2 期
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell LymphomaPeripheral T Cell LymphomaNCT02753543Ruijin Hospital33
Enrolling By Invitation
不适用
Chidamide in Patients With Recurrent and Refractory Diffuse Large bDiffuse Large B-cell LymphomaNCT05690191Second Affiliated Hospital of Soochow University169
招募中
2 期
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DELDouble-expressor LymphomaNCT06674096Zhejiang Cancer Hospital44
Unknown
不适用
Rituximab Combined With Chidamide and Lenalidomide for r/r AITLAngioimmunoblastic T-cell LymphomaChemotherapy EffectChemotherapeutic ToxicityNCT04319601Zhejiang Cancer Hospital26